Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.

Autor: Kimura T; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Obata A; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Shimoda M; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Okauchi S; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Kanda-Kimura Y; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Nogami Y; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Moriuchi S; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Hirukawa H; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Kohara K; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Nakanishi S; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Mune T; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan., Kaku K; Department of General Internal Medicine 1, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan., Kaneto H; Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan.
Jazyk: angličtina
Zdroj: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Oct; Vol. 20 (10), pp. 2442-2457. Date of Electronic Publication: 2018 Jul 05.
DOI: 10.1111/dom.13400
Abstrakt: Aims: We compared the protective effects of sodium glucose co-transporter (SGLT) 2 inhibitor luseogliflozin on pancreatic β-cells between early and advanced stages of diabetes and between short- and long-term use.
Materials and Methods: Diabetic db/db mice were treated with luseogliflozin for 2 weeks in an early stage of diabetes (7-9 weeks of age) and an advanced stage of diabetes (16-18 weeks) for a longer period of time (7-18 weeks). We performed various morphological analyses of pancreatic islets and examined gene expression profiles in islets after such treatment.
Results: In diabetic db/db mice, insulin biosynthesis and secretion were markedly increased by luseogliflozin in an early stage of diabetes but not in an advanced stage. In addition, β-cell mass was preserved by luseogliflozin only in an early stage. Furthermore, when db/db mice were treated with luseogliflozin for a longer period of time, starting from an early stage, β-cell function and mass were markedly preserved even after a longer period of time compared to untreated db/db mice.
Conclusion: Luseogliflozin exerts more protective effects in an early stage of diabetes compared to an advanced stage, and longer-term use of luseogliflozin exerts more beneficial effects on pancreatic β-cells compared to short-term use.
(© 2018 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: